Hand of the Market
Screener
Sectors
Compare
Insider buys
Funds
 Screener

HRMY Harmony Biosciences Holdings, Inc.

Compare with sector and industry Screen the industry

Health Care · Pharmaceuticals & Biotechnology · data as of 2026-10-22 · latest quarter 2026-06-30, filed 2026-08-04

Market cap
$2.09B
P/E (trailing)
11.6×
P/E vs. sector
0.4×
Avg daily $ volume
$39.9M
Days to next report
12
Quality checklist

3 of 4 checks passed · quarter ending 2026-06-30

  • ROIC at least 10%28.7%
  • Operating margin up over 3 years−5.4 pp
  • Free cash flow at least 80% of net income—
  • Share count up at most 5% in 3 years-3.1%
  • Net debt at most 3× EBITDA—
  • Revenue grew over 3 years24.4%
Insider buying, last 90 days

No discretionary insider buying in the last 90 days.

Tracked funds, latest reports
Active managers
+$16.16M +0.7 pp of the company
3 buying · 0 selling · 3 holding
Mutual funds & ETFs
+$27.1K −0.0 pp of the company
1 buying · 1 selling · 3 holding

Each factor with its sector median and, where it's reported per quarter, its last 12 quarters.

Size & liquidity
HRMYSector12 quartersMarket cap$2.09B$9.67BEnterprise value$1.7B$10.41BAvg daily $ volume$39.9M$132.68MDaily turnover1.9%1.3%
Growth
HRMYSector12 quartersRevenue CAGR 3y24.4%9.5%40.7% → 24.4%Revenue CAGR 5y32.5%8.9%Revenue growth YoY30.3%8.7%36.7% → 30.3%Revenue acceleration+13.7 pp+0.0 pp+11.3 pp → +13.7 ppFCF growth YoY—5.9%21.6% → 59.1%FCF conversion—130.8%185.0% → 219.2%Forward growth (HoM est.)27.4%9.8%
Valuation
HRMYSector12 quartersP/E (trailing)11.6×27.6×P/E (forward, HoM est.)9.1×25.2×P/E vs. sector0.4×1.0×PEG (HoM est.)0.333.12EV/EBITDA—17.5×EV/Sales1.8×3.3×FCF yield—3.6%Dividend yield0.0%0.0%Shareholder yield0.0%1.2%
Quality
HRMYSector12 quartersQuality checks passed33ROIC28.7%9.2%47.8% → 28.7%Gross profitability52.7%32.6%56.2% → 52.7%Gross margin75.4%60.1%80.6% → 75.4%Gross margin Δ 3y−5.4 pp−0.1 pp−3.2 pp → −5.4 ppOperating margin24.0%10.6%36.8% → 24.0%Operating margin Δ 3y−5.4 pp+0.9 pp+3.4 pp → −5.4 ppDebt/equity0.2×0.7×0.4× → 0.2×Net debt/EBITDA—2.0×-0.6× → -1.9×Interest coverage17.1×4.9×8.2× → 17.1×Share count Δ 3y-3.1%-0.3%3.0% → -3.1%Stock compensation / revenue4.3%1.8%5.6% → 4.3%Accruals ratio-14.0%-4.3%-2.6% → -14.0%
Earnings & estimates
HRMYSector12 quartersDays to next report1213
Ownership & positioning
HRMYSector12 quartersInsider buys (90d)00Insiders buying (90d)00Insider net value (90d)-$3.11M$0Institutional ownership93.2%99.6%Institutional Δ QoQ−4.1 pp+1.1 ppConviction funds net buying—−0.0 ppActive managers net buying+0.7 pp+0.1 ppActive funds net buying−0.0 pp+0.0 ppDays to cover4.994.29Short % of shares out9.5%6.0%Short interest Δ+1.6 pp+0.1 pp

Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use. Terms of use

Source: SEC EDGAR: Forms 4 (insider trades), 10-Q and 10-K (financials). Insider trades as filed (amendments applied); financial metrics computed by Hand of the Market from the companies' quarterly and annual reports. Each trade links to its filing.

Not investment advice. These signals are starting points for research, not recommendations. Data may contain errors or lag the filings.